Skip to main content
Fig. 6 | Molecular Medicine

Fig. 6

From: Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels

Fig. 6

Effect of the combination of F-Lip-2-AS HER-2 ODN and docetaxel on MDA-MB-435 xenograft tumors. Day 0 is the tumor volume (—100 mm3) prior to initiation of treatment. F-Lip-2-AS HER-2 ODN and docetaxel were intravenously administered. Tumor volumes (mm3) are the average of 4–10 tumors ± SE. Error bars for the combination of F-Lip-2-AS HER-2 ODN and docetaxel are too small to be visualized on the graph.

Back to article page